Rockefeller Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
Other funds holding XENE
Rockefeller Capital Management's XENE Position: Q3 2026 in Review
Rockefeller Capital Management increased its Xenon Pharmaceuticals (XENE) stake by 4% in Q3 2026, buying an estimated $475 and bringing the position to 208 shares worth $7.74K. The position accounts for ﹤0.01% of the portfolio, ranked #4261.
Rockefeller Capital Management first reported a position in XENE in Q3 2025 and has held it in 5 quarters since. The position peaked at $49.3K in Q4 2025. 286 funds tracked by Wall St. Rank hold XENE as of Q3 2026.
- Rockefeller Capital Management held 208 shares of Xenon Pharmaceuticals worth $7.74K as of Q3 2026.
- Rockefeller Capital Management bought 8 Xenon Pharmaceuticals shares in Q3 2026, an estimated $475.
- Xenon Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4261 holding.
- Rockefeller Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
- Rockefeller Capital Management's Xenon Pharmaceuticals position peaked at $49.3K in Q4 2025.
- 286 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.